fropenem has been researched along with Escherichia coli Infections in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, J; Dantas, G; Das, S; Gandra, S; Green, SJ; Harazin, M; McElvania, E; Singh, KS; Thomson, RB | 1 |
| Fujii, S; Fujino, K; Hashimoto, J; Hiyama, Y; Ichihara, K; Masumori, N; Shinagawa, M; Takahashi, S; Uehara, T | 1 |
2 other study(ies) available for fropenem and Escherichia coli Infections
| Article | Year |
|---|---|
Faropenem resistance causes in vitro cross-resistance to carbapenems in ESBL-producing Escherichia coli.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Escherichia coli Infections; Humans; Porins | 2020 |
The efficacy of faropenem for patients with acute cystitis caused by extended spectrum β-lactamase producing Escherichia coli.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cystitis; Escherichia coli; Escherichia coli Infections; Female; Humans; Male; Middle Aged; Retrospective Studies; Young Adult | 2017 |